Vaxcyte

Vaxcyte uses its cell-free protein synthesis platform to create high-fidelity vaccines targeting invasive pneumococcal disease, Group A Strep, and Shigella with distinct protein carriers and antigens.

Vaxcyte develops high-fidelity vaccines using advanced chemistry and synthetic techniques, including cell-free protein synthesis, to produce complex proteins with enhanced immunological benefits.

Bacteria evade the immune system through physical, biochemical, and immunological defenses, requiring vaccines with multiple antigens, serotypes, or immune-enhancing components for broad, durable protection.

The page highlights the growing importance of vaccines in preventing serious diseases, including pneumococcal vaccines for *Streptococcus pneumoniae*, which is worsened by antimicrobial resistance.

Vaxcyte aims to eliminate bacterial infections like invasive pneumococcal disease, Group A Strep, and Shigella to protect children and at-risk adults worldwide.

This Privacy Policy applies to vaxcyte.com and all other sites and services linking to this Privacy Policy (the "Service"). For the purposes of this Privacy Policy, unless otherwise noted, all references to Vaxcyte also include vaxcyte.com. The Vaxcyte website is an informational site.

Vaxcyte closes a $1.15 billion financing round comprising 8.6 million shares of common stock at $64 per share, pre-funded warrants for 400,000 shares at $63.999 each, and $575 million in 1.50% convertible senior notes. The company, focused on vaccine innovation, secures capital through underwritten public offerings, including full exercise of underwriter options.

Oct 2026Vaxcyte, Inc.News article

Vaxcyte’s VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, meets all prespecified primary endpoints in the OPUS-1 Phase 3 trial across adult age groups. The results compare favorably against Prevnar 20® (PCV20) and Capvaxive® (PCV21). The trial evaluates VAX-31’s efficacy and safety in preventing pneumococcal infections.

Oct 2026Vaxcyte, Inc.News article

Vaxcyte reports its second-quarter 2026 financial results, highlighting progress in its adult vaccine pipeline. The company expects topline safety, tolerability, and immunogenicity data from the **VAX-31 Phase 3 OPUS-1 trial** in the fourth quarter of 2026. Additional Phase 3 trial results for **OPUS-2 and OPUS-3** are anticipated in the first half of 2027.

Aug 2026Vaxcyte, Inc.News article

Vaxcyte closes its initial public offering of **17.97 million shares**, including an additional **2.34 million shares** purchased via underwriters’ option. The biotech company develops vaccines targeting common and deadly infectious diseases. Proceeds fund further vaccine research and development.

Jun 2020Vaxcyte, Inc.News article